- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | RenovoRx, Inc.: Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting | 2 | GlobeNewswire (USA) | ||
| 08.04. | RenovoRx, Inc.: RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum | 1 | GlobeNewswire (USA) | ||
| 01.04. | RenovoRx, Inc.: RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | 1 | GlobeNewswire (USA) | ||
| 31.03. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | RenovoRx, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 30.03. | RenovoRx GAAP EPS of -$0.32 in-line, revenue of $1.12M misses by $0.18M | 1 | Seeking Alpha | ||
| 30.03. | RenovoRx, Inc.: RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update | 529 | GlobeNewswire (Europe) | RenovoCath- Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated... ► Artikel lesen | |
| 27.03. | RenovoRx ernennt Dr. Ramtin Agah zum Executive Chairman und passt Vergütung an | 3 | Investing.com Deutsch | ||
| 26.03. | RenovoRx surpasses 100 patients in Phase III pancreatic trial | 7 | Investing.com | ||
| 23.03. | RenovoRx, Inc.: RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement | 3 | GlobeNewswire (USA) | ||
| 23.03. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | RenovoRx announces $10 million private placement | 1 | Seeking Alpha | ||
| 18.03. | RenovoRx sichert sich 10 Mio. US-Dollar durch überzeichnete Privatplatzierung | 2 | Investing.com Deutsch | ||
| 18.03. | RenovoRx raises $10M in oversubscribed private placement | 1 | Investing.com | ||
| 18.03. | RenovoRx, Inc.: RenovoRx Announces $10 Million at Market Private Placement | 1 | GlobeNewswire (USA) | ||
| 27.02. | RenovoRx, Inc.: RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum | 2 | GlobeNewswire (USA) | ||
| 10.02. | RenovoRx, Inc.: RenovoRx Establishes RenovoCath Medical Advisory Board | 1 | GlobeNewswire (USA) | ||
| 06.02. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | RenovoRx, Inc.: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer | 201 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| MODERNA | 43,480 | +0,49 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| BIOGEN | 156,62 | -0,43 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| ILLUMINA | 109,30 | +0,15 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,400 | +4,25 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| TEMPUS AI | 44,665 | +0,42 % | Tempus AI Nears Profitability as Operating Leverage Emerges | ||
| ATAIBECKLEY | 3,880 | -2,02 % | Trader-Interview mit Bastian Galuschka SAP, BASF, ATAIBeckley, Kalvista, MarvellTechnology, Echostar | In dieser Ausgabe des Trader-Interviews analysieren Lothar Albert und Bastian Galuschka die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit speziellem Fokus auf technische Signale, fundamentale... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,515 | +0,43 % | Why Recursion Pharmaceuticals Inc (RXRX) Expanded Citeline Partnership | ||
| TWIST BIOSCIENCE | 49,150 | -5,52 % | Guggenheim reiterates Twist Bioscience stock rating on Amazon tie-up | ||
| OCULAR THERAPEUTIX | 8,100 | 0,00 % | Ocular Therapeutix, Inc.: Ocular Therapeutix to Host Investor Day on June 17, 2026 | ||
| BIOXCEL THERAPEUTICS | 0,930 | +2,20 % | BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of... ► Artikel lesen | |
| PDS BIOTECHNOLOGY | 0,802 | +4,16 % | Weekly Buzz: FDA Okays Travere Therapeutics, Royal Philips; Rejects Replimune; American Industrial Partners Snaps Up Avanos Medical; PDS Biotechnology, Hoth Therapeutics, Spyre Therapeutics, Paces Trials | INDIANAPOLIS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Taiwan, and Europe, alongside FDA rejections, collaborations, acquisitions, and positive... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,252 | +1,61 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights | Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 9,055 | +1,17 % | Kyverna Therapeutics-Aktie: Weiter auf dem Vormarsch | Die Aktie von Kyverna Therapeutics erhält nach neuen Studiendaten weiteren Rückenwind. Erste klinische Ergebnisse der CAR-T-Therapie Mivocabtagene Autoleucel deuten auf eine außergewöhnlich starke Wirksamkeit... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,865 Euro und damit -3,89 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.